ReviewEuropean journal of microbiology & immunology2022
Tuberculosis challenges: Resistance, co-infection, diagnosis, and treatment.
Review in European journal of microbiology & immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Epidemiology of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: A systematic review and meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023Pooled it
- Investigating the Antimycobacterial, Antibiofilm, and Antioxidant Activities of Plant Extracts AgainstMicroorganisms · 2026Article
- Series 2: Invisible Threats: A Global Scoping Review of Risk Factors for Tuberculosis Infection.Tropical medicine and infectious disease · 2026Review
- Factors associated with false-negative results from the rapid molecular test for pulmonary tuberculosis in the state of São Paulo, Brazil.Revista brasileira de epidemiologia = Brazilian journal of epidemiology · 2026Article
- Immune activation and response dynamics of human iPSC-derived macrophages in tuberculosis infection models.Clinical & translational immunology · 2026Article
- NR4A nuclear receptor expression in human macrophages mediates apoptosis and controls Mycobacterium tuberculosis growth.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Article
- Analysis of factors influencing high infectivity in patients with tuberculosis using clinical and imaging methods.BMC infectious diseases · 2025Article
- Synergistic Effects of Curcumin and Antibiotics Against Drug-Sensitive and Multidrug-ResistantInternational journal of molecular sciences · 2025Article
- Pulmonary Complications in Connective Tissue Disease-Associated Interstitial Lung Disease.The clinical respiratory journal · 2025Review
- FuNTB: a functional network clustering tool for the analysis of genome-wide genetic variants in Mycobacterium tuberculosis.Bioinformatics (Oxford, England) · 2025Article
- Functionalized Polydopamine Nanoparticles: A Promising Drug Delivery Platform for the Treatment of Tuberculosis.Drug development research · 2025Review
- Disseminated tuberculosis in an immunocompetent healthy young male with nonspecific symptoms: challenges toward diagnosis-a case report.Journal of medical case reports · 2025Article
- A comparative study on TB incidence and HIVTB coinfection using machine learning models on WHO global TB dataset.Scientific reports · 2025Article
- Incidence and determinants of extrapulmonary tuberculosis in Egypt: a retrospective cohort study.Scientific reports · 2025Article
- Diagnostic value of neutrophil-to-lymphocyte ratio, fibrinogen-to-albumin ratio and red blood cell distribution width in tuberculosis combined with other bacterial infections.BMC pulmonary medicine · 2025Article
- Synergistic anti-inflammatory and anti-tb effects of Au-Pt-Cu nanofluids: experimental and computational insights.Future medicinal chemistry · 2025Article
- Burden of tuberculosis in Eastern Africa region from 1990-2021: A systematic analysis for the Global Burden of Disease 2021 Study.PloS one · 2025Article
- BACTERIAL AND FUNGAL INFECTIONS IN PULMONARY TUBERCULOSIS PATIENTS AND THE DRUG SENSITIVITY TEST PATTERNS.African journal of infectious diseases · 2025Article
- Prevalence and Clinical Implications of Pyrazinamide Resistance in Newly Diagnosed TB Patients in Uganda.Infection and drug resistance · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early diagnosis of tuberculosis (TB), followed by effective treatment, is the cornerstone of global TB control efforts. An estimated 3 million cases of TB remain undetected each year. Early detection and effective management of TB can prevent severe disease and reduce mortality and transmission. Intrinsic and acquired drug resistance of Mycobacterium tuberculosis (MTB) severely restricted the anti-TB therapeutic options, and public health policies are required to preserve the new medications to treat TB. In addition, TB and HIV frequently accelerate the progression of each other, and one disease can enhance the other effect. Overall, TB-HIV co-infections show an adverse bidirectional interaction. For HIV-infected patients, the risk of developing TB disease is approximately 22 times higher than for persons with a protective immune response. Analysis of the current TB challenges is critical to meet the goals of the end TB strategy and can go a long way in eradicating the disease. It provides opportunities for global TB control and demonstrates the efforts required to accelerate eliminating TB. This review will discuss the main challenges of the TB era, including resistance, co-infection, diagnosis, and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.